GlassScriptPhysician profile
August A Feola
NPI 1629051438
$3,649.03
in general payments reported to CMS, 2019-2025
26 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $383 · 2021: $892 · 2022: $895 · 2023: $251 · 2024: $443 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $354.32 | 2020-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $351.73 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $333.65 | 2019-2024 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $286.10 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $276.68 | 2019-2022 | |
| Amgen INC. | $246.49 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $244.56 | 2021-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $167.01 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.94 | 2022 | |
| Genentech USA, INC. | $131.32 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $125.00 | 2021 | |
| Sk Life Science, INC. | $124.99 | 2022 | |
| Merck Sharp & Dohme LLC | $117.04 | 2019-2025 | Lagevrio |
| Sunovion Pharmaceuticals INC. | $113.64 | 2022 | |
| Neurocrine Biosciences, INC. | $101.85 | 2024 | Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $99.23 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $77.65 | 2022-2025 | Rexulti |
| Abbvie INC. | $75.59 | 2021-2025 | |
| Allergan, INC. | $60.25 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $50.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $47.40 | 2022-2023 | Xarelto |
| Lundbeck LLC | $29.94 | 2025 | Rexulti |
| Exact Sciences Corporation | $24.41 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $17.48 | 2025 | Zoryve |
| Pfizer INC. | $16.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw August Feola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.